Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Everolimus for Refractory Seizures in Focal Cortical Dysplasia Type II
NCT03198949Phase 2Completed
- Sponsor
- Yonsei University
- Start
- May 2018
- Primary completion
- Sep 2020
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial in focal cortical dysplasia type II (FCD-II) and epilepsy comparing Everolimus First Arm with Placebo First Arm (2 arms). Primary endpoint: The number of patients who experience seizure reduction of 50% or more. Started May 2018; status: completed.
02
Drugs
everolimus
03
Conditions
focal cortical dysplasia type II (FCD-II)epilepsy
Beyond the preview
Go deeper on NCT03198949.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03198949.